OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Investigational Drugs is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Navafenterol for chronic obstructive pulmonary disease therapy	101
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?	80
Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials	76
Novel experimental and early investigational drugs for the treatment of bipolar disorder	74
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	73
Investigational drugs for HIV: trends, opportunities and key players	69
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	62
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	58
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia	55
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma	52
The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized stu	50
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities	49
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a nov	49
Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus	42
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	41
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	40
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	40
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	36
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	32
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	32
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	31
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	31
Lessons learned from early-stage clinical trials for diabetic nephropathy	30
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	26
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights	26

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia